Introduction

Niemann-Pick disease (NPD) is a group of metabolic disorders in which abnormal amounts of lipids (fatty materials such as waxes, oils, and cholesterol) build up in the brain, spleen, liver, lungs, and bone marrow.¹

The disease has three types, with type A being the most severe and affecting infants. Type B, starting in preteens, causes ataxia and nerve damage. This type spares the brain, with longer survival rates, but with lung issues and type C, varying from childhood to adulthood onset, leads to severe neurological damage and can cause early death.¹

In 1961, Crocker identified 4 types of the disease: NP types A (NPA), B (NPB), C (NPC), and D (NPD). In 1966, it was discovered that NPA and NPB are linked to a deficiency in the enzyme acid sphingomyelinase (ASM), while NPC and NPD are due to issues with cholesterol transport within cells. Therefore, the disease is divided into two main categories: (I) NPA and NPB and (II) NPC and NPD.²

Emotional challenges are present in any disease, especially in rare ones like Niemann-Pick disease. There is still hope for individuals facing such a diagnosis. The emotional well-being of individuals diagnosed with Niemann-Pick disease results from cooperation between several factors such as family, health specialists and the patient himself. Long-term disease management involves counselling, holistic treatment, and patient and caregiver education. 

Improving the emotional well-being of people with NPD requires a holistic approach. Continue reading for a better understanding of the facets of this diagnosis. Access the bibliographic references with confidence. 

Symptoms

Symptoms may include ataxia, loss of muscle tone, brain degeneration, increased sensitivity to touch, spasticity, slurred speech, swallowing difficulties, eye paralysis, learning problems, enlarged liver and spleen, corneal clouding, and a cherry-red halo on the retina.¹

Niemann-Pick type A symptoms manifest in early infancy with slow growth, enlarged liver (hepatomegaly) and spleen (splenomegaly), psychomotor delays, and a cherry-red spot in the eyes. 

Type B symptoms appear in mid-childhood, causing frequent lung infections, enlarged liver and spleen, slower bone growth, low platelet levels, and occasional neurological issues. 

Type C can present at any age, typically in childhood, with symptoms such as muscle spasms, hoarse voice, swallowing difficulties, liver and lung disease, coordination problems, and eye movement issues, alongside cognitive and balance impairments. 

Additional symptoms can include reduced lung function, interstitial lung disease, jaundice, high cholesterol, impaired long bone growth, slower bone mineralisation, hip deformities, corneal clouding, peripheral nerve damage, and tremors.³

Neurological symptoms 

Commonly reported neurological symptoms include memory loss, problems with executive functioning, and symptoms related to psychosis, such as delusions, hallucinations, and paranoia. Concerns about declining sensorimotor functions encompass ataxia, difficulty swallowing, slurred speech, fear of falling, balance issues, and impaired gait. 

Cognitive challenges like loss of working memory or difficulty planning simple tasks, as well as psychosocial difficulties like trouble with verbal communication and feelings of isolation, are significant concerns for both patients and caregivers. Life-threatening symptoms such as difficulty swallowing and motor-related issues are also critical concerns.⁴

Mood disorders, although less common than schizophrenia-like psychosis, are poorly quantified in the literature due to categorisation and reporting where the term "mood disorder/symptom" may include depression, emotional lability or irritability, or hypomania.⁵

Treatment 

Some disease-modifying treatments are available for NPC, but their validation is still being sought, the studies not being conclusive at present.⁶

•  Miglustat, an orally available drug, has been shown to stabilise or slow cerebellar volume loss and slow the loss of white matter micro-integrity in adult patients. This drug is usually given up to 200 mg three times a day, with diarrhoea as a possible side effect because miglustat inhibits disaccharidases in the gut
• Hydroxypropyl-β-cyclodextrin (HPCD) is a drug that is also administered orally. It was accidentally discovered and has been shown to significantly improve neuronal cholesterol homeostasis, decrease neuronal pathology with intrathecal administration, and promise in slowing disease progression in humans⁵
• The U.S. Food and Drug Administration (FDA) has approved Xenpozyme (olipudase alfa-rpcp) for treating non-central nervous system (non-CNS) symptoms of acid sphingomyelinase deficiency (ASMD) in both adults and children. Xenpozyme is the first and currently the only approved therapy specifically for ASMD⁶

Support

The National Niemann-Pick Disease Foundation (NNPDF) has compiled a list of care centres experienced in treating and managing Niemann-Pick disorders.

Addressing emotional well-being in individuals with Niemann-Pick disease (NPD) and mental health is crucial due to the severe nature of the disease. Early recognition is essential to slow progression and manage complications. Since NPD is an autosomal recessive disease, genetic counselling and genetic testing are vital for families at risk. 

Managing NPD requires an interprofessional team, including specialists and support from nurses, social workers, and genetic counsellors. Comprehensive patient education and social support are key components. Effective management involves ensuring patients and caregivers have adequate resources and support, highlighting the importance of treatment compliance, and promoting active collaboration among healthcare team members. This holistic approach helps address the emotional and mental health challenges faced by individuals with NPD.⁷

One of the most challenging aspects of this condition is the impossibility of predicting how the individual's health and development will change over time. In the long run, it can be helpful to connect with other people living with Niemann-Pick disease. Depending on the needs, it is advisable to inquire about which organisations support individuals with such conditions and ask for their support. Participating in clinical trials, usually supported by these organisations, can offer access to possible effective treatments.⁸

The International Niemann-Pick Disease Alliance (INPDA) offers support resources developed by patients and patient groups around the world, providing useful links to each of the INPDA member groups.⁹

FAQs

How does Niemann-Pick disease affect the brain?

Neurological complications can lead to significant brain damage, resulting in the inability to move the eyes up and down, difficulties with walking and swallowing, and a gradual vision and hearing loss.

How rare is Niemann-Pick disease?

Niemann-Pick disease type C (NPC) is estimated to occur in 1 in every 100,000-120,000 live births. However, many cases are either misdiagnosed or undiagnosed, complicating the determination of its actual prevalence in the general population.⁹

How long can you live with Niemann-Pick disease?

While Niemann-Pick disease is always fatal, the prognosis depends on when the disease is diagnosed. Life expectancy varies, with some children living into their late teens or early twenties, while others with milder forms of the disease may live into adulthood.

Summary

• Niemann-Pick disease is a metabolic disorder where lipids accumulate in organs like the brain, liver, and spleen. It has three types:
  • Type A: Severe, affects infants with slow growth and neurological issues
  • Type B: Appears in mid-childhood with lung infections, liver/spleen enlargement, and slower bone growth
  • Type C: Varies in onset, typically in childhood, causing severe neurological damage
• It is classified into four types (NPA, NPB, NPC, NPD), with NPA and NPB linked to enzyme deficiency and NPC and NPD to cholesterol transport issues
• Symptoms include memory loss, motor function decline, and cognitive difficulties
• Treatments like Miglustat and hydroxypropyl-β-cyclodextrin show promise. Xenpozyme is an FDA-approved medicine for non-CNS symptoms
• Emotional well-being is vital, requiring early recognition, genetic counselling, and an interprofessional care team
• Support organisations and clinical trials can offer additional help and resources